Emilie Barruet, PhD
University of California, San Francisco
Characterizing the abnormal immune responses in FOP

Esmée Botman, PhD
VU University Medical Center
Using novel imaging to identify a silent ‘’chronic’’ state of FOP

Andrew Garner, PhD
Blueprint Medicines
Animal and lab data on BLU-782, a potential treatment for FOP

Sarah J. Hatsell, PhD
Regeneron Pharmaceuticals
The role of Activin A in heterotopic ossification (HO) formation in FOP Mice with a R258G mutation

Fred Kaplan, MD
University of Pennsylvania
Phase 2 data showing the effect of palovarotene on new HO

Ina Kramer, PhD
Novartis Institutes for BioMedical Research
Animal and lab data on SF-86-HL84, a potential treatment for FOP

Daniel S. Perrien, PhD
Vanderbilt University
(1) Characterizing the immune response before new bone formation
(2) The source and role of Activin A in HO

Ton Schoenmaker, BSc
Academic Centre for Dentistry Amsterdam (ACTA)
The role of Activin A and FOP bone remodeling

Alexandra Stanley
University of Pennsylvania 
Characterizing muscle tissue repair in FOP cells

Kelly Wentworth, MD
University of California, San Francisco
Genetic differences in people with more “mild” FOP